Tech Company Financing Transactions
OKYO Pharma Funding Round
OKYO Pharma, based in London, secured $1.4 million in investment from private investors.
Transaction Overview
Company Name
Announced On
1/22/2025
Transaction Type
Venture Equity
Amount
$1,400,000
Round
Undisclosed
Investors
Proceeds Purpose
The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on fueling progress with OKYO's lead program, OK-101 focused on treating NCP, a major unmet medical need.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
London, Undisclosed
UK
London, Undisclosed
UK
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat NCP and inflammatory DED. In addition to the completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also currently evaluating OK-101 to treat NCP patients in a Phase 2 trial.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gary Jacob
Browse more venture capital transactions:
Prev: 1/22/2025: Addis Energy venture capital transaction
Next: 1/22/2025: Project Eaden venture capital transaction
Share this article
About Our VC Transactions Data
We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs